This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Krystal Biotech Stock Surges 21.9% in 3 Months: More Room to Grow?
by Zacks Equity Research
KRYS has gained 21.9% in the past three months on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.
ILMNNegative Net Change KRYSNegative Net Change FULCNegative Net Change
biotechnology biotechs medical pharmaceuticals
JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
by Zacks Equity Research
The Johnson & Johnson filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.
JNJPositive Net Change ARGXPositive Net Change FULCNegative Net Change BVSNegative Net Change
biotechs medical pharmaceuticals
Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data
by Zacks Equity Research
MRK made this decision after an independent committee pointed out that Keytruda did not show improvement in certain types of lung and skin cancers.
AZNPositive Net Change MRKPositive Net Change FULCNegative Net Change BVSNegative Net Change
biotechs medical pharmaceuticals
EBS Stock Rises on FDA Nod for ACAM2000 in Mpox Indication
by Zacks Equity Research
The FDA approves Emergent BioSolutions' sBLA seeking a label expansion of ACAM2000 for the mpox indication. Stock rises in pre-market trading.
ILMNNegative Net Change EBSPositive Net Change KRYSNegative Net Change FULCNegative Net Change
biotechs
GSK's RSV Vaccine Arexvy Gets EU Nod for Adults Aged 50-59 Years
by Zacks Equity Research
The European Commission approves GSK's RSV vaccine, Arexvy, for use in adults aged 50-59 years with increased risk of the disease.
GSKNegative Net Change PFEPositive Net Change ILMNNegative Net Change MRNAPositive Net Change
biotechs
SWTX's NDA for Rare Tumor Drug Gets Priority Review From FDA
by Zacks Equity Research
The FDA accepts and grants priority review to SpringWorks' NDA for mirdametinib for treating neurofibromatosis type 1-associated plexiform neurofibromas.
ILMNNegative Net Change KRYSNegative Net Change FULCNegative Net Change
biotechs
Bull Of The Day: Bioventus (BVS)
by Brian Bolan
This stock has seen 3 consecutive beats of the Zacks Consensus Estimate and also posted solid margin expansion.
BVSNegative Net Change
biotechs hmo hospitals medical
Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs
by Zacks Equity Research
PFE's digital pharmacy aims to provide patients easy access to its medicines for COVID-19, migraine and other conditions.
PFEPositive Net Change LLYNegative Net Change FULCNegative Net Change BVSNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Why Viking Therapeutics Stock Price Moved Down 6% on Tuesday
by Zacks Equity Research
VKTX's shares fell after rival Eli Lilly announced that it is launching cheaper versions of Zepbound to strengthen its presence in the obesity market.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
Addex Stock Soars on Crucial Update From Indivior Research Deal
by Zacks Equity Research
ADXN gains 55% on a crucial update from its GABAB PAM research collaboration with INDV. Both companies pick pre-clinical compounds for IND-enabling studies.
JNJPositive Net Change FULCNegative Net Change ADXNPositive Net Change INDVPositive Net Change
biotechnology biotechs medical pharmaceuticals
Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review
by Zacks Equity Research
SLNO stock gains 6.3% as FDA accepts regulatory filing for lead candidate, DCCR, to treat hyperphagia associated with PWS under Priority Review.
ACADNegative Net Change SLNONegative Net Change FULCNegative Net Change BVSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
by Ekta Bagri
Regeneron (REGN) and Lexicon (LXRX) are in the spotlight following drug approval and regulatory update, respectively.
REGNNegative Net Change LXRXNegative Net Change GLPGPositive Net Change RYTMNegative Net Change
biotechnology biotechs medical pharmaceuticals
Roche Obtains Approval For its Rare Blood Disorder Drug in the EU
by Zacks Equity Research
RHHBY gets approval for PiaSky for treating patients suffering from paroxysmal nocturnal hemoglobinuria in the EU.
AZNPositive Net Change RHHBYPositive Net Change LLYNegative Net Change EXELNegative Net Change
biotechnology biotechs medical pharmaceuticals
Ocugen to Begin Phase III Study on Eye Drug in Canada, Stock Up
by Zacks Equity Research
OCGN receives Health Canada's No Objection Letter to begin a phase III study on OCU400 for treating retinitis pigmentosa. Shares rise.
ILMNNegative Net Change FULCNegative Net Change OCGNNegative Net Change
biotechs
Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma
by Zacks Equity Research
REGN's oncology portfolio gets a boost with the approval of odronextamab for treating follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).
REGNNegative Net Change SNYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Insmed Stock Surges 168% in the Past Six Months: Here's Why
by Zacks Equity Research
Shares of INSM soar after it reports positive data from two clinical studies that highlight its encouraging progress with its lung disorder drugs.
AZNPositive Net Change INSMPositive Net Change FULCNegative Net Change BVSNegative Net Change
biotechs medical pharmaceuticals
Rhythm Stock Up as FDA Accepts Obesity Drug sNDA for Younger Kids
by Zacks Equity Research
RYTM gains 8% as FDA accepts Imcivree sNDA seeking label expansion of the drug to treat obesity in kids as young as two years old.
ARCTNegative Net Change RYTMNegative Net Change FULCNegative Net Change BVSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Gilead (GILD) Gains 16.8% in 3 Months: How Should You Play the Stock?
by Zacks Equity Research
While Gilead's (GILD) performance has been good in the past three months on robust second-quarter results and pipeline progress, we will wait before recommending the stock.
GSKNegative Net Change GILDNegative Net Change MRUSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why
by Zacks Equity Research
The recent regulatory setbacks related to Zentalis' (ZNTL) lead pipeline candidate, azenosertib, weigh heavily on the stock.
GSKNegative Net Change ILMNNegative Net Change FULCNegative Net Change ZNTLPositive Net Change
biotechs
AstraZeneca (AZN) Denies Rumors About UK Facility Relocation
by Zacks Equity Research
Per third-party reports, AstraZeneca (AZN) has refuted rumors about considering a change in the relocation of a vaccine manufacturing plant from the U.K. to the United States.
AZNPositive Net Change ARCTNegative Net Change FULCNegative Net Change BVSNegative Net Change
biotechs medical pharmaceuticals vaccines
Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why
by Zacks Equity Research
Sutro Biopharma (STRO) gains 9% in a week after initiating a phase II study on its lead candidate, luvelta, to treat FRa-expressing lung cancer.
ARCTNegative Net Change STROPositive Net Change FULCNegative Net Change BVSNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Here's Why You Should Invest in SpringWorks (SWTX) Stock Now
by Zacks Equity Research
Here, we are discussing some reasons why investing in SpringWorks (SWTX) stock now may turn out to be a prudent move.
ILMNNegative Net Change FULCNegative Net Change BVSNegative Net Change
biotechs
Alkermes (ALKS) Begins Narcolepsy Type 2 Study on ALKS 2680
by Zacks Equity Research
Alkermes' (ALKS) phase II Vibrance-2 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with narcolepsy type 2.
ALKSNegative Net Change JAZZPositive Net Change AXSMPositive Net Change FULCNegative Net Change
biotechs
FDA Approves Pfizer & Moderna's Updated COVID-19 Jabs
by Sundeep Ganoria
On Thursday, the FDA cleared new versions of Pfizer's (PFE) and Moderna's (MRNA) COVID-19 vaccines that are designed to match COVID-19 strains currently circulating in the country.
PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXNegative Net Change
biotechs medical pharmaceuticals vaccines
Viking (VKTX) Rises 25% in a Month: Should You Buy or Wait?
by Sundeep Ganoria
Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.
NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change MDGLPositive Net Change
biotechs medical pharmaceuticals